Artivion (NYSE:AORT) Given "Sell (D-)" Rating at Weiss Ratings

Key Points

• Weiss Ratings has reissued a "sell (D-)" rating for Artivion (NYSE:AORT), indicating concerns about the stock's performance.
• Despite mixed ratings from various analysts, the consensus rating for Artivion is "Moderate Buy" with an average target price of $43.97.
• Artivion reported $0.24 earnings per share for the last quarter, exceeding expectations, and showing a 15.3% revenue growth year-over-year.

Artivion (NYSE:AORT - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Friday,Weiss Ratings reports.

A number of other analysts have also weighed in on the company. LADENBURG THALM/SH SH lowered Artivion from a "buy" rating to a "neutral" rating and raised their target price for the company from $32.00 to $38.80 in a research note on Wednesday, August 13th. Stifel Nicolaus raised their price target on Artivion from $40.00 to $46.00 and gave the company a "buy" rating in a report on Monday, September 29th. Citigroup reiterated an "outperform" rating on shares of Artivion in a report on Friday, October 10th. Wall Street Zen upgraded Artivion from a "hold" rating to a "buy" rating in a report on Monday, August 25th. Finally, JMP Securities raised their price target on Artivion from $42.00 to $47.00 and gave the company a "market outperform" rating in a report on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $43.97.

Artivion Price Performance

Artivion stock traded up $0.02 during mid-day trading on Friday, hitting $43.42. 352,132 shares of the company were exchanged, compared to its average volume of 430,136. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52. The business has a fifty day moving average of $41.99 and a 200 day moving average of $33.62. Artivion has a 1-year low of $21.97 and a 1-year high of $45.07. The company has a market capitalization of $2.05 billion, a PE ratio of -103.38 and a beta of 1.67.

Artivion (NYSE:AORT - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.13. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The company had revenue of $112.97 million during the quarter, compared to analyst estimates of $107.96 million. The firm's revenue for the quarter was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Artivion will post 0.37 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Marshall S. Stanton sold 18,200 shares of Artivion stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $44.02, for a total transaction of $801,164.00. Following the transaction, the senior vice president owned 64,200 shares in the company, valued at $2,826,084. The trade was a 22.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Jean F. Holloway sold 23,356 shares of Artivion stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $43.01, for a total value of $1,004,541.56. Following the transaction, the senior vice president owned 172,129 shares in the company, valued at $7,403,268.29. This trade represents a 11.95% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 74,858 shares of company stock worth $3,250,129. Company insiders own 7.60% of the company's stock.

Hedge Funds Weigh In On Artivion

Several institutional investors have recently modified their holdings of AORT. MCF Advisors LLC lifted its holdings in shares of Artivion by 109.3% during the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock valued at $29,000 after purchasing an additional 614 shares in the last quarter. Smartleaf Asset Management LLC raised its position in Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock valued at $52,000 after buying an additional 538 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Artivion by 447.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,410 shares of the company's stock valued at $168,000 after buying an additional 4,422 shares during the last quarter. Diversified Trust Co acquired a new stake in Artivion in the 3rd quarter valued at approximately $200,000. Finally, James Investment Research Inc. acquired a new stake in Artivion in the 2nd quarter valued at approximately $210,000. Institutional investors own 86.37% of the company's stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.